Kuros Biosciences announced three advancements related to its MagnetOs portfolio of products: specifically positive results from the MAXA level 1 clinical trial comparing standalone MagnetOs to autog… [+2886 chars]
Kuros Biosciences Announces Three Advancements Related to its MagnetOs Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
